Abstract
Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have